Back to Authors

Reschke, Cole

A5035934190 | I1279571640

Mayo Clinic

Alzheimer's Association

Citations 5

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2014.07.069

P2‐141: BRAIN‐DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2014.05.816

DT‐01–06: Baseline FDG‐PET and volumetric MRI predicts Alzheimer's disease conversion from mild cognitive impairment: An ADNI study

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.007

O3‐06‐08: Sample size estimates for pre‐symptomatic Alzheimer's disease treatment/surrogate marker development trials in Apolipoprotein E4 homozygotes close to their estimated age at symptomatic onset

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2010.05.434

O1–05–03: PET measurements of posterior cingulate glucose metabolism are superior to MRI measurements of hippocampal volume in distinguishing cognitively normal persons at differential genetic risk for Alzheimer's disease

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.070